Omnicell Announces Third Quarter 2025 Financial Results

Omnicell delivers strong third quarter financial results

Results exceed previously issued third quarter 2025 guidance on all metrics

Raises full year 2025 total revenues, non-GAAP EBITDA and non-GAAP EPS guidance

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell,” “we,” “our,” “us,” “management,” or the “Company”), a leader in transforming the pharmacy and nursing care delivery model, today announced results for its third quarter ended September 30, 2025.

“We are pleased with the strong financial performance delivered in the third quarter, with total revenues, non-GAAP EBITDA and non-GAAP EPS all exceeding the upper end of our previously issued guidance,” stated Randall Lipps, chairman, president, chief executive officer, and founder of Omnicell. “This quarter our flagship point-of-care connected devices continued to be the core driver for our business. Going forward, our transformation to an intelligent medication management technology company is expected to position us to deliver new innovations that are designed to continually improve the customer experience and to help our customers advance closer to the industry-defined vision of the Autonomous Pharmacy, while also driving value for our stakeholders over the long-term.”

Financial Results

Total revenues for the third quarter of 2025 were $311 million, up $28 million, or 10%, from the third quarter of 2024. The year-over-year increase in total revenues was driven by strength in our connected devices and technical services offerings, as well as increases in our consumables and SaaS and Expert Services revenues.

Total GAAP net income for the third quarter of 2025 was $5 million, or $0.12 per diluted share. This compares to GAAP net income of $9 million, or $0.19 per diluted share, for the third quarter of 2024.

Total non-GAAP net income for the third quarter of 2025 was $24 million, or $0.51 per diluted share. This compares to non-GAAP net income of $26 million, or $0.56 per diluted share, for the third quarter of 2024.

Total non-GAAP EBITDA for the third quarter of 2025 was $41 million. This compares to non-GAAP EBITDA of $39 million for the third quarter of 2024.

Balance Sheet

As of September 30, 2025, Omnicell’s balance sheet reflected cash and cash equivalents of $180 million, total debt (net of unamortized debt issuance costs) of $167 million, and total assets of $1.9 billion. Cash flows provided by operating activities in the third quarter of 2025 totaled $28 million. This compares to cash flows provided by operating activities totaling $23 million in the third quarter of 2024.

During the third quarter of 2025, the Company repaid the remaining principal balance of $175 million of the convertible senior notes that matured on September 15, 2025, as well as repurchased approximately 1,987,000 shares of its common stock for an aggregate purchase price of approximately $62 million.

As of September 30, 2025, the Company had $350 million of availability under its revolving credit facility with no outstanding balance.

Corporate Highlights

• Ballad Health, a 21-hospital health system supporting rural healthcare across 29 counties throughout northeast Tennessee and southwest Virginia, recently announced the addition of IV compounding robotics in an effort to help further improve medication accuracy and patient safety for critical medications delivered through the health system’s central fill pharmacy. According to Trish Tanner, chief pharmacy officer at Ballad Health, “By expanding automation into IV compounding, we find we are further improving accuracy, reducing risk, and strengthening our commitment to patients.”
• Omnicell’s Specialty Pharmacy Services business has been awarded the Healthcare Management Certification, Version 3.0 by the Utilization Review Accreditation Commission, the nation’s leading independent accreditor of healthcare organizations, known for rigorous standards and focus on continuous improvement. We believe the certification further affirms Omnicell’s commitment to delivering patient-centered services that are designed to improve outcomes in a compliant manner while advancing and improving performance for healthcare facilities.
• The Company will showcase its latest innovations designed to empower autonomous medication management across all care settings at the upcoming American Society of Health-System Pharmacists (ASHP) Midyear 2025 Clinical Meeting and Exhibition, December 7-11, 2025, in Las Vegas, Nevada. These new solutions are focused on driving intelligent outcomes, including delivering a better clinician experience, expanding visibility and oversight for pharmacy enterprise, enhancing safety and accuracy in the IV cleanroom, and transforming outpatient care delivery.

2025 Guidance

The table below summarizes Omnicell’s fourth quarter and updated full year 2025 guidance. Given the strength of our performance during the first three quarters of 2025 and visibility into the fourth quarter of the year, we are reaffirming our full year 2025 product bookings and Annual Recurring Revenue outlook and modestly raising our full year 2025 total revenues, non-GAAP EBITDA and non-GAAP EPS guidance.

The Company does not provide guidance for GAAP net income or GAAP earnings per share, nor a reconciliation of any forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measures on a forward-looking basis, because it is unable to predict certain items contained in the GAAP measures without unreasonable efforts. These forward-looking non-GAAP financial measures do not include certain items, which may be significant, including, but not limited to, unusual gains and losses, costs associated with future restructurings, acquisition-related expenses, and certain tax and litigation outcomes.

Omnicell Conference Call Information

Omnicell will hold a conference call today, Thursday, October 30, 2025, at 8:30 a.m. ET to discuss third quarter 2025 financial results. The conference call can be monitored by dialing (800) 715-9871 in the U.S. or (646) 307-1963 in international locations. The Conference ID is 3131192. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell’s website at https://ir.omnicell.com/events-and-presentations/.

About Omnicell

Since 1992, Omnicell has been committed to transforming pharmacy and nursing care through outcomes-centric solutions designed to deliver clinical and business outcomes across all settings of care. Through a comprehensive portfolio of robotics and smart devices, intelligent software workflows, and data and analytics, all optimized by expert services, Omnicell solutions are helping healthcare facilities worldwide to uncover cost savings, improve labor efficiency, establish new revenue streams, enhance supply chain control, support compliance, and move closer to the industry-defined vision of the Autonomous Pharmacy. To learn more, visit omnicell.com.

From time to time, Omnicell may use the Company’s investor relations website and other online social media channels, including its LinkedIn page www.linkedin.com/company/omnicell, and Facebook page www.facebook.com/omnicellinc, to disclose material non-public information and comply with its disclosure obligations under Regulation Fair Disclosure (“Reg FD”).

OMNICELL and the Omnicell logo are registered trademarks of Omnicell, Inc. or one of its subsidiaries. This press release may also include the trademarks and service marks of other companies. Such trademarks and service marks are the marks of their respective owners.

Forward-Looking Statements

To the extent any statements contained in this press release deal with information that is not historical, these statements are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, statements including the words “expect,” “intend,” “may,” “will,” “should,” “would,” “could,” “plan,” “potential,” “anticipate,” “believe,” “forecast,” “guidance,” “outlook,” “goals,” “target,” “estimate,” “seek,” “predict,” “project,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to the occurrence of many events outside Omnicell’s control. Such statements include, but are not limited to, Omnicell’s projected product bookings, revenues, including product, service, technical services and SaaS and Expert Services revenues, annual recurring revenue, non-GAAP EBITDA, and non-GAAP earnings per share; expectations regarding our products and services and developing new or enhancing existing products and solutions and the related objectives and expected benefits (and any implied financial impact); our ability to deliver, and our customers’ receptivity to new innovations that are designed to improve the customer experience and advance customers closer to the industry-defined vision of the Autonomous Pharmacy; our ability to drive value for all our stakeholders over the long-term; and statements about Omnicell’s strategy, plans, objectives, promise and purpose, vision, goals, opportunities, and market or Company outlook. Actual results and other events may differ significantly from those contemplated by forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things, (i) unfavorable general economic and market conditions, including the impact and duration of inflationary pressures, (ii) Omnicell’s ability to take advantage of growth opportunities and develop and commercialize new solutions and enhance existing solutions, (iii) reduction in demand in the capital equipment market or reduction in the demand for or adoption of our solutions, systems, or services, (iv) delays in installations of our medication management solutions or our more complex medication packaging systems, (v) our international operations may subject us to additional risks, including from the impact of tariffs, (vi) risks related to Omnicell’s investments in new business strategies or initiatives, including its transition to selling more products and services on a subscription basis, and its ability to acquire companies, businesses, or technologies and successfully integrate such acquisitions, (vii) risks related to failing to maintain expected service levels when providing our SaaS and Expert Services or retaining our SaaS and Expert Services customers, (viii) Omnicell’s ability to meet the demands of, or maintain relationships with, its institutional, retail, and specialty pharmacy customers, (ix) risks related to climate change, legal, regulatory or market measures to address climate change and related emphasis on ESG matters by various stakeholders, (x) changes to the 340B Program, (xi) risks related to the incorporation of artificial intelligence technologies, including generative or agentic AI technologies, into our products, services and processes or our vendors offerings, (xii) Omnicell’s substantial debt, which could impair its financial flexibility and access to capital, (xiii) covenants in our credit agreement could restrict our business and operations, (xiv) continued and increased competition from current and future competitors in the medication management automation solutions market and the medication adherence solutions market, (xv) risks presented by government regulations, legislative changes, fraud and anti-kickback statues, products liability claims, the outcome of legal proceedings, and other legal obligations related to healthcare, privacy, data protection, and information security, and the costs of compliance with, and potential liability associated with, our actual or perceived failure to comply with such obligations, including any potential governmental investigations and enforcement actions, litigation, fines and penalties, exposure to indemnification obligations or other liabilities, and adverse publicity related to the same; (xvi) any disruption in Omnicell’s information technology systems and breaches of data security or cyber-attacks on its systems or solutions, including the previously disclosed ransomware incident and any potential adverse legal, reputational, and financial effects that may result from it and/or additional cybersecurity incidents, as well as the effectiveness of business continuity plans during any future cybersecurity incidents, (xvii) risks associated with operating in foreign countries, (xviii) Omnicell’s ability to recruit and retain skilled and motivated personnel, (xix) Omnicell’s ability to protect its intellectual property, (xx) risks related to the availability and sources of raw materials and components or price fluctuations, shortages, or interruptions of supply, (xxi) Omnicell’s dependence on a limited number of suppliers for certain components, equipment, and raw materials, as well as technologies provided by third-party vendors, (xxii) fluctuations in quarterly and annual operating results may make our future operating results difficult to predict, (xxiii) failing to meet (or significantly exceeding) our publicly announced financial guidance, and (xxiv) other risks and uncertainties further described in the “Risk Factors” section of Omnicell’s most recent Annual Report on Form 10-K, as well as in Omnicell’s other reports filed with or furnished to the United States Securities and Exchange Commission (“SEC”), available at www.sec.gov. Forward-looking statements should be considered in light of these risks and uncertainties. Readers are encouraged to review this press release in conjunction with our most recent Annual Report on Form 10-K and our other reports filed with or furnished to the SEC. Investors and others are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. Omnicell assumes no obligation to update any such statements publicly, or to update the reasons actual results could differ materially from those expressed or implied in any forward-looking statements, whether as a result of changed circumstances, new information, future events, or otherwise, except as required by law.

Use of Non-GAAP Financial Information

This press release contains financial measures that are not calculated in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”). Management evaluates and makes operating decisions using various performance measures. In addition to Omnicell’s GAAP results, we also consider non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP income (loss) from operations, non-GAAP operating margin, non-GAAP net income, non-GAAP net income per diluted share, non-GAAP diluted shares, non-GAAP EBITDA, non-GAAP EBITDA margin, and non-GAAP free cash flow. These non-GAAP results and metrics should not be considered as an alternative to revenues, gross profit, operating expenses, income from operations, net income, net income per diluted share, diluted shares, net cash provided by operating activities, or any other performance measure derived in accordance with GAAP. We present these non-GAAP results and metrics because management considers them to be important supplemental measures of Omnicell’s performance and refers to such measures when analyzing Omnicell’s strategy and operations.

Our non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP income from operations, non-GAAP operating margin, non-GAAP net income, non-GAAP net income per diluted share, non-GAAP EBITDA, and non-GAAP EBITDA margin are exclusive of certain items to facilitate management’s review of the comparability of Omnicell’s core operating results on a period-to-period basis because such items are not related to Omnicell’s ongoing core operating results as viewed by management. We define our “core operating results” as those revenues recorded in a particular period and the expenses incurred within such period that directly drive operating income in such period. Management uses these non-GAAP financial measures in making operating decisions because, in addition to meaningful supplemental information regarding operating performance, the measures give us a better understanding of how we believe we should invest in research and development, fund infrastructure growth, and evaluate the effectiveness of marketing strategies. In calculating the above non-GAAP results: non-GAAP gross profit and non-GAAP gross margin exclude from their GAAP equivalents items a), b) e), and i) below; non-GAAP operating expenses excludes from its GAAP equivalents items a), b), c), e), f), g), h), and i) below; non-GAAP income from operations and non-GAAP operating margin exclude from their GAAP equivalents items a), b), c), e), f), g), h), and i) below; and non-GAAP net income and non-GAAP net income per diluted share exclude from their GAAP equivalents items a) through i) below. Non-GAAP EBITDA is defined as earnings before interest income and expense, taxes, depreciation, amortization, and share-based compensation, as well as excluding certain other non-GAAP adjustments. Non-GAAP EBITDA and non-GAAP EBITDA margin exclude from their GAAP equivalents items a), c), d), e), f), g), h), and i) below:

Management adjusts for the above items because management believes that, in general, these items possess one or more of the following characteristics: their magnitude and timing is largely outside of Omnicell’s control; they are unrelated to the ongoing operation of the business in the ordinary course; they are unusual and we do not expect them to occur in the ordinary course of business; or they are non-operational or non-cash expenses involving stock compensation plans or other items.

We believe that the presentation of non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP income from operations, non-GAAP operating margin, non-GAAP net income, non-GAAP net income per diluted share, non-GAAP EBITDA, and non-GAAP EBITDA margin is warranted for several reasons:

Kathleen Nemeth
Senior Vice President, Investor Relations
650-435-3318
Kathleen.Nemeth@Omnicell.com